Philippines at a glance
- Population
- 116.8 million 2025
- Life expectancy at birth
- 69.9 years, 2024
- People aged 65 and over
- 5.7 % of people, 2025
- Health spending per person
- 194 US$ per person, 2023
- Doctors
- 0.79 per 1,000 people, 2021
Philippines Neuromodulation for Depression Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$5.2 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $3.1 Mn | — | — |
| 2025 (base) | $3.4 Mn | +$0.3 Mn | — |
| 2026 (forecast) | $3.8 Mn | +$0.4 Mn | +10.8% |
| 2027 (forecast) | $4.2 Mn | +$0.4 Mn | +22.8% |
| 2028 (forecast) | $4.7 Mn | +$0.5 Mn | +36% |
| 2029 (forecast) | $5.2 Mn | +$0.5 Mn | +50.7% |
| 2030 (forecast) | $5.7 Mn | +$0.6 Mn | +67% |
| 2031 (forecast) | $6.4 Mn | +$0.6 Mn | +85% |
| 2032 (forecast) | $7.0 Mn | +$0.7 Mn | +105% |
| 2033 (forecast) | $7.8 Mn | +$0.8 Mn | +127.2% |
| 2034 (forecast) | $8.7 Mn | +$0.8 Mn | +151.7% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Neuromodulation for depression uses magnetic or electrical stimulation of the brain, such as TMS, to treat depression that does not respond to medicines.
Key segments of the neuromodulation for Depression market include technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy and Vagus Nerve Stimulation) and setting (Clinics, Hospitals and Home).
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.
Digital tools, new drug classes and care built into primary care and workplaces give the neuromodulation for Depression market strong room to grow worldwide.
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the neuromodulation for Depression market.
The neuromodulation for Depression market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how neuromodulation for Depression products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Philippines.
What doctors and scientists are doing in Neuromodulation for Depression right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.
[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
From our blog
Philippines · 3 shared keywords
Philippines · 3 shared keywords
Philippines · 3 shared keywords
Philippines · 2 shared keywords
Philippines · 2 shared keywords
Philippines · 2 shared keywords
OTC & Nutraceuticals · Philippines
Pharmaceuticals · Philippines
Digital Health · Philippines
Digital Health · Philippines
Pharmaceuticals · Philippines
Pharmaceuticals · Philippines